TABLE 1.
Clinical and Epidemiologic Characteristics, Treatment and Outcome of 26 Neonatal Cases of SARS-CoV-2 Infections
| ID | Age (Days)/Sex | Diagnosis | Treatment | Hospital Duration (Days) | Hospital Outcome (Age at Death) | Follow-up Outcome (Age at Follow-up/Death) |
|---|---|---|---|---|---|---|
| Ne01 | 0/f | Ruptured myelomeningocele | Ceftriaxone | 3 | Referred | Died (38) |
| Ne02 | 1/f | PNA with HIE stage 2 and congenital pneumonia | Ceftazidime, amikacin, phenobarbitone, Sup 02 | 2 | Died (3) | — |
| Ne03 | 1/f | Ruptured myelomeningocele | Surgical repair, ceftazidime, gentamycin, paracetamol | 3 | Referred | Healthy (59) |
| Ne04 | 1/m | Anocutaneous fistula | Anoplasty, ceftazidime, metronidazole | 3 | Referred | Healthy (61) |
| Ne05 | 1/f | Ruptured occipital encephalocele | Excision and repair of occipital region, ceftriaxone, flucloxacillin, gentamicin, phenobarbitone | 12 | Referred | Healthy (74) |
| Ne06 | 2/m | EONS with anorectal malformation | Nasogastric suction, ceftazidime, amikacin, metronidazol | 1 | Died (4) | — |
| Ne07 | 2/m | PNA with HIE stage 2, pneumonia and EONS | Ceftazidime, amikacin, meropenem, netilmicin, phenobarbitone, Sup 02 | 10 | LAMA | Sick (36) |
| Ne08 | 3/f | EONS with disseminated intravascular coagulation | Ceftazidime, amikacin, meropenem, vancomycin, dopamine, dobutamine, Sup 02 | 5 | Died (8) | — |
| Ne09 | 4/m | EONS, pneumonia, and severe metabolic acidosis | Ceftazidime, amikacin, dopamine, sodium bicarbonate, Sup 02 | 2 | Died (6) | — |
| Ne10 | 4/f | Ruptured myelomeningocele | Ceftriaxone, gentamycin | 4 | Referred | Sick (40) |
| Ne11 | 4/f | EONS | Ceftazidime, amikacin, Sup 02 | 3 | Referred | Healthy (63) |
| Ne12 | 4/m | EONS and neonatal jaundice | Ceftazidime, phototherapy | 3 | Referred | LTFU |
| Ne13 | 4/m | PNA with HIE stage 2, EONS and pneumonia | Ceftazidime, amikacin, meropenem, netilmicin, piperacillin + tazobactam, furosemide, dobutamine, phenobarbitone, Sup 02 | 11 | Referred | LTFU |
| Ne14 | 5/f | EONS and neonatal jaundice | Ceftazidime, amikacin, phenobarbitone, Sup 02 | 5 | Referred | Healthy (49) |
| Ne15 | 8/m | Acute kidney injury due to obstructive uropathy | Ceftazidime, meropenem, sodium bicarbonate, calcium gluconate | 4 | Referred | Sick (63) |
| Ne16 | 8/m | LONS | Ceftazidime, amikacin | 2 | Referred | Healthy (70) |
| Ne17 | 14/m | Posterior urethral valve with bilateral hydroureteronephrosis (grade-3) with bilateral TEV | Ceftazidime, amikacin, meropenem, metronidazole, frusemide, calcium gluconate, sodium bicarbonate | 7 | Referred | Died (28) |
| Ne18 | 19/m | Congenital heart disease, LONS and metabolic acidosis | Meropenem, amikacin, aminophylline, phenobarbitone, Sup 02 | 5 | Referred | Died (25) |
| Ne19 | 22/m | LONS | Ceftazidime, amikacin, Sup 02 | 3 | Referred | Healthy (49) |
| Ne20 | 22/m | LONS | Ceftriaxone, amikacin, phenobarbitone | 8 | Discharged | Healthy (81) |
| Ne21 | 23/m | Congenital heart disease and LONS | Ceftazidime, meropenem, dobutamine, furosemide, calcium gluconate, Sup 02 | 4 | Referred | Died (30) |
| Ne22 | 23/m | Epistaxis due to local trauma | Mupirocin 2% topical ointment | 4 | Referred | Healthy (57) |
| Ne23 | 23/m | Pneumonia | Ceftazidime, amikacin, Sup 02 | 4 | Referred | LTFU |
| Ne24 | 25/f | LONS and pneumonia | Ceftriaxone, amikacin, Sup 02 | 2 | Referred | Healthy (82) |
| Ne25 | 28/f | LONS and pneumonia | Meropenem, amikacin | 4 | LAMA | Healthy (77) |
| Ne26 | 28/m | NA | NA | 6 | Discharged | Healthy (102) |
All ages are in days.
TEV indicates talipes equinovarus; PNA, perinatal asphyxia; AGA, appropriate gastrointestinal age; RDS, respiratory distress syndrome; LTFU, lost to follow-up; LAMA, left against medical advice; NA, not available.